Mihael Hristos Polymeropoulos bought $84k of VNDA
President and CEO at Vanda Pharmaceuticals Inc.. 20,000 shares at an average of $4.22, traded May 16, 2025, filed May 19, 2025.
Score components
- +25RoleCEO
- +9Trade size$84k at market
- -5Relative to holdingsUnder 1% of holdings (0.9%)
- +14Price context6% above the 52-week low; 24% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.1%, 3m +5.8%, 6m +2.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-074565, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 16, 2025 | POpen-market purchase Common Stock | +20,000 | $4.22 | $84k | 2,315,731 | May 19, 2025 |
Related signals
Other insiders at Vanda Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Vanda Pharmaceuticals Inc. | Gunther Birznieks SVP, Business Development | $351k 42,431 shares | -8% | |
| 52Moderate | Vanda Pharmaceuticals Inc. | Kevin Patrick Moran SVP, CFO & Treasurer | $351k 42,442 shares | -9% | |
| 65Notable | Vanda Pharmaceuticals Inc. | Mihael Hristos Polymeropoulos President and CEO | $1.3M 156,235 shares | -5% | |
| 50Moderate | Vanda Pharmaceuticals Inc. | Timothy Williams SVP & General Counsel | $351k 42,434 shares | -10% | |
| 43Moderate | Vanda Pharmaceuticals Inc. | Joakim Wijkstrom SVP, Chief Marketing Officer | $255k 30,800 shares | -8% | |
| 48Moderate | Vanda Pharmaceuticals Inc. | Tage Honore director | $241k 30,000 shares | -24% | |
| 45Moderate | VNDAbuy Vanda Pharmaceuticals Inc. | Mihael Hristos Polymeropoulos President and CEO | $42k 10,000 shares | +0% | |
| 20Weak | VNDAsell Vanda Pharmaceuticals Inc. | Stephen Ray Mitchell director | $32k 7,000 shares | -7% | |
| 35Weak | VNDAbuy Vanda Pharmaceuticals Inc. | Mihael Hristos Polymeropoulos President and CEO | $44k 10,000 shares | +0% | |
| 25Weak | VNDAsell Vanda Pharmaceuticals Inc. | Stephen Ray Mitchell director | $26k 5,000 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.